Illumina and Agilent Technologies to Co-Market Targeted Resequencing Solution
News Apr 21, 2009
Illumina, Inc. and Agilent Technologies announced they have entered into a non-exclusive co-marketing agreement to support a new, scalable solution for researchers conducting targeted resequencing studies. The Agilent SureSelect Target Enrichment System, optimized for Illumina’s widely-adopted next-generation sequencing platform, the Genome Analyzer, provides researchers with a method for resequencing specific regions of interest in the genome.
This approach simplifies the lab process while providing even coverage and high alignment rates. When combined with Illumina’s Genome Analyzer, the Agilent SureSelect Target Enrichment System allows researchers to conduct studies that otherwise would not be feasible.
Illumina and Agilent are highlighting the benefits of their combined solution at the American Association of Cancer Research (AACR) meeting this week in Denver, Colorado. The new research protocol enables scientists to interrogate multiple regions of interest in order to detect rare mutations.
Chad Nusbaum, Co-director of the Genome Sequencing and Analysis program at MIT’s Broad Institute, described the hybrid selection technique utilized by Agilent’s SureSelect technology in the February 2009 issue of Nature Biotechnology.
“We have developed a hybrid-selection method for enriching specific subsets of a genome that is flexible, scalable, and efficient. Targeting based on hybrid selection may be potentially useful for a variety of applications where traditional single-plex PCR is either too costly or too specific. Examples are enrichment of precious ancient DNA that is heavily contaminated with unwanted DNA, deep sequencing of viral populations in clinical samples, or metagenomics analyzes of environmental or medical specimens.”
“A partnership with Agilent underscores our commitment to build upon the utility of our next-generation sequencing technology, helping researchers plan and execute studies at a scale never before possible,” said Jay Flatley, President and CEO of Illumina. “We continue to expand our portfolio of solutions with powerful tools for studying genetic variation. This solution provides the research community with a cost-effective, automation-friendly, and flexible approach to targeted resequencing for a wide variety of applications.”
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE